Research programme: Bcr-Abl tyrosine kinase inhibitors - ACT BiotechAlternative Names: ACTB 1011
Latest Information Update: 01 Apr 2011
At a glance
- Originator ACT Biotech
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Apr 2011 Revised MoA
- 04 Aug 2009 Early research in Cancer in USA (unspecified route)